#China License vs. Global $PVCT License Interest

Many shareholders expected Provectus to announce an MOU with a Chinese pharmaceutical company following Peter's return from China. None yet has materialized. Keep global license interest in PV-10 in mind, however, as management works through geographic license interest in China, India and Japan. The level of seriousness in a global license appears to have markedly increased (Craig's reference to a Big Pharma in due diligence is only one data point), requiring management to balance whether and how to consummate a global license transaction with Big Pharma with whether and how to consummate regional license transactions.